Xellia Pharmaceuticals

What Xellia Pharmaceuticals does

Xellia Pharmaceuticals is a specialty pharmaceutical manufacturer founded in 1903 and headquartered in Copenhagen, Denmark. The company develops, manufactures, and supplies fermentation-based, non-beta-lactam anti-infective active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). It has been wholly owned by Novo Holdings A/S, the investment company of the Novo Nordisk Foundation, since the May 2013 acquisition from the previous owners.

The company's product portfolio spans established anti-infective APIs including Amphotericin B, Bacitracin, Colistimethate sodium, Daptomycin, Gramicidin, Polymyxin B, Tobramycin, Tyrothricin, and Vancomycin, together with finished vial products in Colistimethate sodium, Daptomycin, and Polymyxin B. Manufacturing relies on industrial-scale microbial fermentation and downstream processing across approximately ten global sites — including Copenhagen (HQ and manufacturing), Budapest, Taizhou (under a joint venture with Hisun), and an R&D center in Oslo — supported by EU GMP, US FDA, Japanese DMF, and other multi-jurisdictional regulatory certifications. The pipeline is reported to include Dalbavancin and Fidaxomicin.

Xellia operates a B2B supplier model, selling APIs and FDFs to more than 500 pharmaceutical companies across roughly 80 countries. Revenue is generated through volume-based sales of regulated anti-infective inputs under long-cycle qualification contracts; the company does not publicly disclose revenue. In 2024 management announced a strategic shift away from the integrated API+FDF model toward a specialized fermentation-based API manufacturer, divesting the Bedford, Ohio facility to Hikma Pharmaceuticals for $135 million and a select portfolio package to Hikma for up to $185 million in additional consideration.

Name

Xellia Pharmaceuticals

Legal name

Xellia Pharmaceuticals ApS

Website

https://xellia.com

Company type

Private

Founded year

1903

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Xellia Pharmaceuticals, founded in 1903 and headquartered in Copenhagen, Denmark, manufactures fermentation-based non-beta-lactam anti-infective APIs and finished dosage forms for generic and branded drug manufacturers globally, under Novo Holdings A/S ownership.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAIABAH

Generic Finished Dosage Form (FDF) Manufacturing

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Anti-infective APIs
• Pharmaceutical contract manufacturing
• Fermentation-based API production
• Active pharmaceutical ingredients
• Sterile injectable manufacturing

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Xellia manufactures and supplies fermentation-based non-beta-lactam anti-infective APIs including amphotericin B, bacitracin, colistimethate sodium, daptomycin, vancomycin, polymyxin B, tobramycin, and others to pharmaceutical companies globally.
2. Finished Dosage Forms (FDFs): Specialized injectable finished dosage forms including lyophilized vials and dry-filled vials for critical care anti-infectives such as colistimethate sodium, daptomycin, and polymyxin B.
3. Pipeline Products (Dalbavancin, Fidaxomicin): Development and potential future commercialization of pipeline products including Dalbavancin (US DMF submitted) and Fidaxomicin (under registration in Europe).

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Xellia Pharmaceuticals is a global specialty pharmaceutical manufacturer specializing in fermentation-based non-beta-lactam anti-infective Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company supplies essential antibiotics and antifungals such as amphotericin B, colistimethate sodium, daptomycin, vancomycin, and polymyxin B to more than 500 pharmaceutical companies across 80 countries. EU-based production and 120+ years of uninterrupted supply form the operational backbone of the offering.

Product overview

Xellia Pharmaceuticals is a global leader in fermentation-based non-beta-lactam anti-infectives, offering a portfolio of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company's API portfolio includes Amphotericin B (antifungal), Bacitracin/Bacitracin zinc (polypeptide antibiotics), Colistimethate sodium (polymyxin), Daptomycin (lipopeptide), Gramicidin (polypeptide), Polymyxin B sulfate, Tobramycin sulfate (aminoglycoside), Tyrothricin, and Vancomycin hydrochloride (multiple manufacturing sites: Budapest, Copenhagen, Taizhou). The FDF portfolio includes injectable products such as Colistimethate sodium (dry-filled and lyophilized vials), Daptomycin vials, Daptomycin RT vials, and Polymyxin B vials. The pipeline includes Dalbavancin (US DMF submitted) and Fidaxomicin (under registration in Europe). Xellia supplies APIs and finished dosage forms to more than 500 pharmaceutical companies across 80 countries, with EU-based manufacturing operations and a focus on last-line-of-defence anti-infectives for serious and life-threatening infections.

Differentiator

Problem solved

Functional benefit

Products and services

• Amphotericin B

Quantifiable outcome

• Supplies APIs and finished dosage forms to over 500 pharmaceutical companies across 80 countries
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Hikma PharmaceuticalsminorStrategic or Co-development PartnerHikma acquired Xellia's Bedford, Ohio injectable manufacturing facility in 2024 for $135 million, with additional portfolio acquisition of up to $185 million. Hikma is expanding the facility with a $267 million investment creating 350 jobs, targeting full commercial production by 2028.

Scale indicators5 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Sandoz: Sandoz is the world's largest generics manufacturer and a major supplier of anti-infective APIs and finished dosage forms, including antibiotics. Multiple Xellia C-suite executives (CEO, CBO, CFO) came from Sandoz's anti-infectives and B2B businesses, making it the most directly comparable peer in product portfolio and customer base.
• Centrient Pharmaceuticals: Centrient is a Dutch-headquartered specialty manufacturer of fermentation-based beta-lactam and non-beta-lactam antibiotic APIs, with a focus on sustainable enzymatic and fermentation processes. It competes head-to-head with Xellia in the same anti-infective API category and serves similar pharmaceutical customers globally.
• ACS Dobfar: ACS Dobfar is an Italian API manufacturer specializing in cephalosporins and other fermentation-derived antibiotics, with integrated sterile injectable capabilities. It competes directly with Xellia in fermentation-based anti-infective APIs and injectable finished dosage forms for regulated markets.
• Zhejiang Hisun Pharmaceutical: Hisun is Xellia's joint venture partner at the Taizhou manufacturing site and a major Chinese API manufacturer with a strong anti-infective portfolio including vancomycin. It is both a partner and a direct competitor in global antibiotic API markets.

Broad incumbents

• Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical company with a substantial injectables franchise. It acquired Xellia's Bedford facility and injectable portfolio for up to $320M in 2024, making it a direct downstream competitor in injectable anti-infectives and a strategic counterpart in Xellia's recent refocusing.
• Aurobindo Pharma: Aurobindo is one of the largest Indian generic pharmaceutical manufacturers with extensive API and finished dosage form capabilities across antibiotics. It competes with Xellia across multiple anti-infective molecules and offers cost-competitive alternatives to Western API suppliers.
• Shionogi: Shionogi is a Japanese pharmaceutical company with a leading anti-infectives franchise including established antibiotic franchises. It operates in the same anti-infective therapeutic space and competes for global pharmaceutical customers seeking quality-assured antibiotic APIs and finished forms.
• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a broad anti-infective portfolio spanning APIs and finished forms. While not focused exclusively on anti-infectives, it overlaps with Xellia in supplying generic antibiotic APIs and finished dosage forms to global pharmaceutical customers.
• Viatris: Viatris is a major global generics and specialty pharmaceutical company formed from Mylan and Upjohn, with significant anti-infective capabilities including injectable antibiotics. It serves many of the same 500+ pharmaceutical company customers as Xellia across multiple geographies.
• Cipla: Cipla is a leading Indian pharmaceutical manufacturer with a strong anti-infective and respiratory portfolio, including APIs and finished dosage forms. It competes with Xellia across multiple anti-infective molecules, particularly in emerging markets and via cost-competitive API supply.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/xellia-pharmaceuticals
• Xx.com/xellia
• Facebookfacebook.com/323920734373607

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xellia Pharmaceuticals